MBIO

Mustang Bio, Inc. (MBIO) Business Model Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-09-01

Overall Score

Revenue Model

No meaningful revenue base is evident in the TTM data, with revenue-related valuation ratios at 0 and margins at 0, indicating a pre-commercial or highly distressed profile.

The company’s cash position of $2.25 per share exceeds its book value per share of $1.12, but this does not offset the lack of demonstrated sales generation.

Profitability

TTM profitability remains deeply negative, with return on assets at -19.4%, return on equity at -34.2%, and return on invested capital at -45.8%.

Margins are all reported at 0, and net income per share is -0.45, showing no evidence of operating leverage or earnings durability.

Balance Sheet

Liquidity is acceptable, with a current ratio of 1.97 and a cash ratio of 1.91, suggesting near-term obligations are covered.

Net current asset value and tangible asset value are both about $7.55M, but solvency remains weak given the negative solvency ratio and negative enterprise value.

Cash Flow

Operating cash flow per share is -0.67 and free cash flow per share is -0.67, indicating ongoing cash burn.

Free cash flow to equity is -$4.51M TTM, so the business is not self-funding from internal operations.

Capital Efficiency

Return on capital employed is -45.8%, showing capital is currently being deployed at a significant loss.

Asset turnover and working capital turnover are effectively 0, implying very limited efficiency in converting assets and capital into output.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mustang Bio, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →